Does allogeneic stem cell transplant treat acute lymphoblastic leukaemia?

The treatment replaces blood-forming cells with healthy stem cells from a donor after preparative therapy. The donor immune system may also recognise and attack leukaemia cells, an effect that can strengthen the treatment's action.

A transplant is not part of every acute lymphoblastic leukaemia plan. Specialists may consider it when disease features suggest a greater chance of return, when leukaemia remains after initial therapy, or when it has come back. Test results showing response at a very sensitive level help shape this decision.

Suitability also depends on general health, organ function, previous treatment, donor availability, and the person's priorities. The potential for prolonged control must be weighed against infection, organ injury, graft-versus-host disease, infertility, and other effects of intensive treatment.

The transplant team performs blood tests, tissue matching, infection screening, and checks of the heart, lungs, liver, and kidneys. Tell them about every prescribed medicine, supplement, allergy, previous infection, dental issue, and any fertility or pregnancy concern before preparative treatment begins.

After donor cells are infused, close monitoring continues while new blood cells develop. Follow instructions about infection exposure, food safety, mouth care, medicines, and clinic tests. A reliable caregiver and practical plans for travel and accommodation may be needed during early recovery.

Contact the transplant service immediately for fever at its stated threshold, shaking chills, a new rash, persistent diarrhoea or vomiting, jaundice, worsening breathlessness, unusual bleeding, severe mouth pain, or reduced urine. These may signal infection, graft-versus-host disease, or another complication requiring rapid treatment.

Call emergency services for collapse, confusion, severe breathing difficulty, chest pain, uncontrolled bleeding, or facial swelling with trouble breathing. Show the transplant alert information if one was provided and give the date of the transplant and current immune-suppressing medicines.

Ask why transplant is recommended at this point, how the leukaemia has responded, how a donor will be selected, which preparative treatment is planned, and how graft-versus-host disease will be prevented and monitored. Discuss fertility, vaccinations, returning to work or school, and whom to call at any hour.